Clinical application value of chemokine detection kits in the diagnosis of inflammatory and autoimmune diseases

Chemokine Networks in Inflammatory and Autoimmune Diseases

In chronic inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease, chemokines such as CCL2, CCL3, and CXCL8 (IL-8) mediate the migration of monocytes and neutrophils to lesion sites; whereas in systemic autoimmune diseases such as systemic lupus erythematosus and Sjögren's syndrome, CXCL13 and CXCL12 are involved in lymphoid follicle formation and B cell activation. Chemokine detection kits can simultaneously measure multiple related targets, helping clinicians understand patients' abnormal immune chemotactic status at the molecular level. Compared with single indicators, multi-factor profiles can provide richer pathophysiological information.

Auxiliary Role of Detection Kits in Disease Diagnosis

Some autoimmune diseases lack specific antibody markers in the early stages, and chemokine expression profiles may provide supplementary evidence. For example, elevated serum CCL4 has been reported in systemic sclerosis-associated interstitial lung disease, and elevated CXCL13 levels in synovial fluid are associated with the progression of joint erosion in rheumatoid arthritis. When using chemokine detection kits for auxiliary differential diagnosis, it is usually necessary to combine routine laboratory indicators and imaging results. The detection limit and linear range of the kit should accommodate the concentration span of different body fluid samples. For instance, chemokine concentrations in serum and synovial fluid may differ by several orders of magnitude, requiring the selection of an appropriate dilution scheme.

For Disease Activity Monitoring and Treatment Evaluation

During treatment, dynamic detection of chemokine levels is expected to reflect changes in disease activity. For example, in rheumatoid arthritis patients who respond effectively to anti-TNF therapy, serum CXCL8 concentrations often show a downward trend; whereas in systemic lupus erythematosus patients, CXCL10 levels may rise in advance before disease relapse. If a chemokine detection kit adopts a multiplex technology platform, it can perform parallel quantification of multiple factors in a single run, facilitating the plotting of individual patient chemokine fluctuation curves. However, some chemokines exhibit circadian rhythms or are affected by drugs, and standardization of sampling time is a prerequisite for comparability of monitoring results. The standards provided in the kit should be strictly traceable to international reference preparations to ensure data consistency across different laboratories.

Considerations and Prospects in Clinical Application

At present, before chemokine detection kits can be routinely used in clinical laboratories, they still need to undergo sufficient performance validation, including precision, accuracy, and anti-interference capability. Sample collection should use tube types free of interfering components, and plasma or serum should be separated and stored at low temperature as soon as possible. In addition, reference intervals for chemokines may differ among healthy populations of different ethnicities and ages. The ranges stated in kit instructions should be used as reference rather than diagnostic cutoff values. With the iteration of multiplex detection technologies and increasing automation, chemokine detection kits are expected to become an important component of the precision diagnostic toolbox in rheumatology and immunology.